These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 15625210)
21. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268 [TBL] [Abstract][Full Text] [Related]
22. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Krakowski MI; Czobor P; Citrome L; Bark N; Cooper TB Arch Gen Psychiatry; 2006 Jun; 63(6):622-9. PubMed ID: 16754835 [TBL] [Abstract][Full Text] [Related]
23. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Tollefson GD; Sanger TM; Lu Y; Thieme ME Arch Gen Psychiatry; 1998 Mar; 55(3):250-8. PubMed ID: 9510219 [TBL] [Abstract][Full Text] [Related]
24. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. Kinon BJ; Roychowdhury SM; Milton DR; Hill AL J Clin Psychiatry; 2001; 62 Suppl 2():17-21. PubMed ID: 11232746 [TBL] [Abstract][Full Text] [Related]
25. A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior. Chan HY; Ree SC; Su LW; Chen JJ; Chou SY; Chen CK; Chen YS J Clin Psychopharmacol; 2014 Jun; 34(3):355-8. PubMed ID: 24743717 [TBL] [Abstract][Full Text] [Related]
26. Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. Saddichha S; Manjunatha N; Ameen S; Akhtar S J Clin Psychiatry; 2007 Nov; 68(11):1793-8. PubMed ID: 18052574 [TBL] [Abstract][Full Text] [Related]
28. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I; J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069 [TBL] [Abstract][Full Text] [Related]
29. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Buchanan RW; Breier A; Kirkpatrick B; Ball P; Carpenter WT Am J Psychiatry; 1998 Jun; 155(6):751-60. PubMed ID: 9619146 [TBL] [Abstract][Full Text] [Related]
30. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981 [TBL] [Abstract][Full Text] [Related]
31. Efficacy of olanzapine and risperidone in schizophrenia: a randomized double-blind crossover design. Canive JM; Miller GA; Irwin JG; Moses SN; Thoma RJ; Edgar JC; Sherwood A; Torres F; Lanoue M; Lewis S; Hanlon FM; Weisend MP; Mead V; Tuason VB Psychopharmacol Bull; 2006; 39(1):105-16. PubMed ID: 17065975 [TBL] [Abstract][Full Text] [Related]
35. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. Sayers SL; Campbell EC; Kondrich J; Mann SC; Cornish J; O'Brien C; Caroff SN J Nerv Ment Dis; 2005 Jun; 193(6):379-86. PubMed ID: 15920378 [TBL] [Abstract][Full Text] [Related]
36. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. McGlashan TH; Zipursky RB; Perkins D; Addington J; Miller T; Woods SW; Hawkins KA; Hoffman RE; Preda A; Epstein I; Addington D; Lindborg S; Trzaskoma Q; Tohen M; Breier A Am J Psychiatry; 2006 May; 163(5):790-9. PubMed ID: 16648318 [TBL] [Abstract][Full Text] [Related]
37. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Lecrubier Y; Quintin P; Bouhassira M; Perrin E; Lancrenon S Acta Psychiatr Scand; 2006 Nov; 114(5):319-27. PubMed ID: 17022791 [TBL] [Abstract][Full Text] [Related]
38. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. Buchanan RW; Panagides J; Zhao J; Phiri P; den Hollander W; Ha X; Kouassi A; Alphs L; Schooler N; Szegedi A; Cazorla P J Clin Psychopharmacol; 2012 Feb; 32(1):36-45. PubMed ID: 22198451 [TBL] [Abstract][Full Text] [Related]
39. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Breier A; Hamilton SH Biol Psychiatry; 1999 Feb; 45(4):403-11. PubMed ID: 10071708 [TBL] [Abstract][Full Text] [Related]
40. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V; JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]